Funding

Florida-Based DermaSensor Raises $4M in Series B Extension Funding

Sep 10, 2026 | By Devin Jacobs

SUMMARY

DermaSensor raised $4M in Series B funding.
Funds will support growth and nationwide expansion.
DermaSensor builds an AI skin cancer device.

DermaSensor Inc., a Miami-based medical device company providing an AI-powered skin cancer diagnostic technology platform, has raised $4 million in Series B extension funding, bringing its total funding to $48 million. The backers were not disclosed.

The company plans to use the fresh capital to build commercial infrastructure for nationwide access to its device and accelerate growth.

Funding Snapshot

Metric	Details
Fundraise Amount	$4 million
Total Funding	$48 million
Valuation	Not disclosed
Company	DermaSensor Inc.
Sector	Healthcare / Medical Devices / AI
Headquarters	Miami, Florida, USA
Lead Investor	Not disclosed

RECOMMENDED FOR YOU

Funding

[Funding alert] San Francisco-based Opal Security Secures $22M in Series B Round Funding

Devin Jacobs

Dec 8, 2023

AlTi Tiedemann Global Acquired East End Advisors

Devin Jacobs

Apr 1, 2024

Funding

Portal Biotechnologies Raises $9M in Funding Round Led by NFX

Devin Jacobs

Jun 19, 2026

About DermaSensor

Founded in 2009 by Cody Simmons, DermaSensor is a Miami-based medical device company that helps healthcare professionals check suspicious skin lesions for skin cancer. Its technology was originally developed at Boston University and combines Elastic Scattering Spectroscopy (ESS) with artificial intelligence to provide an immediate, objective risk result.

The company said its device is already used by hundreds of healthcare provider organizations and has been used to scan more than 45,000 suspicious lesions.

Core offerings include:

AI-powered skin cancer risk assessment
Elastic Scattering Spectroscopy technology
Non-invasive handheld diagnostic device
Immediate objective risk results

Core Technologies / Products / Services

Capability/Product	Application/Use Case
DermaSensor™ Device	Provides an immediate result for skin cancer risk
Elastic Scattering Spectroscopy	Analyzes suspicious skin lesions
Artificial Intelligence	Supports objective skin cancer risk assessment
Non-Invasive Scanning	Enables healthcare professionals to check suspicious lesions

Leadership Comments

“Our professional investor partners have supported us through every phase of building this new medical device category. Opening the financing on Wefunder is about extending that ownership to the physicians and patients who are living the problem we're solving, given that 1 in 5 Americans are affected by skin cancer. We want the people closest to it to have a seat at the table,” said Cody Simmons, Co-Founder and CEO of DermaSensor.